FRAMINGHAM, Mass., April 20, 2016 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ: HTWR), a leading innovator of
less-invasive, miniaturized circulatory support technologies that
are revolutionizing the treatment of advanced heart failure, today
announced a series of scientific presentations, highlighting the
clinical and commercial use of the HVAD® System, at the
International Society for Heart and Lung Transplantation (ISHLT)
36th Annual Meeting and Scientific Sessions to be held at the
Marriott Wardman Park Hotel in Washington, D.C. on April 27-30, 2016.
Key Oral Presentations
"Temporal Changes in Adverse
Events in the ENDURANCE Trial"
C. A. Milano, F. D.
Pagani, A. J. Tatooles,
N. A. Mokadam, J. Miller,
T. C. Wozniak, C. H. Selzman, K. Leadley, K. D. Aaronson, J. G.
Rogers
Presenter: Dr. Milano (Duke University School of Medicine)
Thursday, April 28 at 10:30 a.m. ET
"Impact of Baseline Measures and Adverse Events on Functional
Assessments in the ENDURANCE Destination Therapy Trial"
J. G. Rogers, C. A. Milano, S. V.
Pamboukian, G. Bhat, E. J.
Birks, S. S. Najjar,
B. B. Reid, D. Meyer, K. Leadley,
F. D. Pagani
Presenter: Dr.
Rogers (Duke University School of
Medicine)
Thursday, April 28 at 2:00 p.m. ET
"Less-Invasive Left Ventricular Assist Device Implantations:
Experience After More Than 100 Treated Patients"
J. D. Schmitto, S. V. Rojas, M. Avsar, J. S. Hanke, A. Uribarri, D. Burkhoff, K.
Tümler, P. Ahrens, U. Molitoris, A. Martens, D. Berliner, J.
Bauersachs, M. Shrestha, S. Cebotari, M. Strueber, A.
Haverich
Presenter: Dr. Schmitto (Hannover Medical School,
Germany)
Thursday, April 28 at 5:00 p.m. ET
"HVAD Waveform as a Surrogate Marker of Cardiac Index and
Pulmonary Capillary Wedge Pressure"
J. Grinstein,
D. E. Rodgers, S. Kalantari Tannenbaum, S. Adatya, N. Sarswat,
G. H. Kim, G. Sayer, T. Ota, V.
Jeevanandam, V. Mor-Avi, D.
Burkhoff, N. Uriel
Presenter: Dr. Grinstein (University of Chicago)
Friday, April 29 at 10:45 a.m. ET
HeartWare Scientific Symposiums
In conjunction with the ISHLT Annual Meeting, HeartWare will host
two symposiums for clinicians:
HVAD Pump Waveforms: Real-Time,
Non-Invasive Monitoring
Wednesday,
April 27, 3:50 p.m. –
4:50 p.m.; Washington Ballroom 3
Moderators: Prof. Chris Hayward
(St. Vincent's Hospital,
Sydney, Australia); Dr.
Mark Slaughter (Jewish Hospital,
Louisville)
Presenters: Dr. Samer Najjar
(Washington Hospital Center); Prof. Daniel
Zimpfer (Medical University Vienna, Austria) and Dr. Jeffrey Teuteberg (University of Pittsburgh Medical Center)
Advancements in HVAD
Outcomes
Thursday, April 28,
12:55 p.m. – 1:55 p.m.; Washington Ballroom 3
Moderators: Dr. Jennifer Cowger,
(St. Vincent Hospital, Indianapolis); Prof. Michiel Morshuis (Bad Oeynhausen, Germany)
Presenters: Dr. Ed McGee
(Loyola University Medical Center); Dr.
Carmelo Milano (Duke University School of Medicine) and Prof.
Stephan Schueler (Newcastle
Hospital, U.K.)
"HeartWare will have a strong and positive presence at this
important scientific conference that attracts thousands of renowned
cardiovascular clinicians from around the world," said Katrin Leadley, M.D., Chief Medical Officer of
HeartWare International. "We are honored that the HVAD System
is the subject of more than 90 abstracts, reinforcing the
real-world, commercial experience, while highlighting the utility
and versatility of the device."
Additional Oral Presentations and Scientific Posters
Highlighting the HVAD System
"Incidence and Outcomes
After Stroke on Rotary Flow Ventricular Assist Device Support"
(poster presentation)
M. Bishawi, J. Joseph, B.
Yerokun, D. Ranney, P. Winterton, J. Schroder, M. Daneshmand, D.
Bowles, J. Rogers, C. Milano
Wednesday, April 27 at 6:00 p.m. ET
"Global Experience With the HeartWare HVAD in Pediatric
Patients: A Preliminary Analysis"
J. Conway, O. Miera, H.
T. Henderson, C. VanderPluym, H. Buchholz, M. Fenton, R. A.
Niebler, M. Padalino, M. Slaughter, A. Lorts, M. Schweiger,
M. Hassan, J. D. Schmitto,
J. N. Scheel, B. Martin, Y. Li, P. E.
Parrino, D. L. Morales, R.
Kirk
Thursday, April 28 at
4:00 p.m. ET
"Lessons Learned From Over 250 Continuous-Flow Centrifugal
Left Ventricular Assist Device Implantation: Growing Experience and
Outcomes in Alternative Approaches Era"
S. Maltais, N.
Haglund, P. Shah, J. Cowger, K. A.
Aaronson, F. Pagani, S. Dunlay, J.
M. Stulak
Thursday, April
28 at 4:45 p.m. ET
"Minimally Invasive HeartWare HVAD Implantation With Outflow
Graft Anastomosis to the Left Subclavian Artery" (poster
presentation)
J. Riebandt, D. Wiedemann, T. Haberl, T.
Schloeglhofer, R. Moayedifar, K. Dimitrov, G. Laufer, D.
Zimpfer
Thursday, April 28 at
6:00 p.m. ET
"Increased Risk of Gastrointestinal Bleeding in HeartMate II
Compared to HeartWare Left Ventricular Assist Devices - A Single
Center Retrospective Cohort"
W.
T. Love, G. M. Zawadowski, J.
Noelting, J. L. Horsley-Silva,
L. L. Staley, M. E. Amity, L.
Schroedl, M. D. Crowell,
B. W. Hardaway, F. C. Ramirez, O. E.
Pajaro.
Thursday, April
28 at 6:50 p.m. ET
"Invasive Hemodynamic Ramp Test: A Comparison of Ventricular
Unloading Between Current Generation Continuous-Flow LVADs"
K. Abdullah, N. Badoe, S. Phillips,
J. Nabut, R. Singh, S. S. Desai, P.
Shah
Friday, April 29 at
10:30 a.m. ET
"Minimally Invasive Exchange of the HeartMate II (HMII) Left
Ventricular Assist Device (LVAD) to the Intrapericardial HeartWare
Ventricular Assist Device (HVAD)"
B. Soleimani, B. Burk,
E. Stephenson, W. Pae
Friday, April
29 at 11:45 a.m. ET
"Agreeing to Disagree: A Comparison of Antiplatelet and
Anticoagulant Management Strategies at U.S. Versus International
HVAD Implanting Centers" (poster presentation)
J. J. Teuteberg, K. D. Aaronson, C. Mahr, H. Reichenspurner, T.
Krabatsch, C. B. Patel, M. Strueber,
M. S. Kiernan, D. Zimpfer,
M. V. Jacoski, S. Schueler
Friday, April 29 at 6:00 p.m. ET
Please note that this news release refers to third-party
presentations of material related to the HVAD System and that the
views expressed at ISHLT by any speaker or panelist who is not an
employee of HeartWare or its subsidiaries do not necessarily
reflect the views of HeartWare International, Inc.
About the HeartWare® Ventricular Assist
System
The HVAD® System, is HeartWare's flagship product and
features the world's smallest full-support circulatory assist
device, the HVAD Pump, and is designed to be implanted next to the
heart, avoiding the abdominal surgery generally required to implant
other devices. The HeartWare System received CE Marking in
the European Union in 2009 and was approved by the U.S. Food and
Drug Administration in 2012 as a bridge to cardiac transplantation
for patients who are at risk of death from refractory end-stage
left ventricular heart failure. The device is also currently
the subject of a U.S. clinical trial for destination therapy.
Today, more than 10,000 patients with advanced heart failure
in 47 countries around the world have received the HVAD System.
About HeartWare International
HeartWare International develops and manufactures miniaturized
implantable heart pumps, or ventricular assist devices, to treat
patients around the world suffering from advanced heart
failure. Dedicated to developing new, minimally invasive
technologies to revolutionize the treatment of patients with
end-stage heart failure, HeartWare has multiple technologies in
development to offer progressively less-invasive mechanical
circulatory support options. HeartWare's corporate
headquarters are located in Framingham,
Massachusetts, and the company has technology, operations,
manufacturing and distribution centers in Miami Lakes, Florida; Arden Hills, Minnesota; and Hannover, Germany. For additional
information about the company, please visit www.heartware.com.
HEARTWARE, HVAD, MVAD, PAL, SYNERGY, CIRCULITE and HeartWare
logos are trademarks of HeartWare, Inc. or its
affiliates.
Forward-Looking Statements
This announcement contains forward-looking statements that are
based on management's beliefs, assumptions and expectations and on
information currently available to management. All statements that
address operating performance, events or developments that we
expect or anticipate will occur in the future are forward-looking
statements, including without limitation our expectations with
respect to the: commercialization of the HeartWare HVAD System and
timing, progress and outcomes of clinical trials; regulatory
submissions and quality compliance; investigation, research and
development activities; and our ability to take advantage of
acquired and pipeline technology. Management believes that these
forward-looking statements are reasonable as and when made.
However, you should not place undue reliance on forward-looking
statements because they speak only as of the date when made.
HeartWare does not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
by federal securities laws and the rules and regulations of the
Securities and Exchange Commission (SEC). HeartWare may not
actually achieve the plans, projections or expectations disclosed
in forward-looking statements, and actual results, developments or
events could differ materially from those disclosed in the
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties, including without
limitation those described in Part I, Item 1A. "Risk Factors" in
HeartWare's Annual Report on Form 10-K filed with the SEC.
HeartWare may update risk factors from time to time in Part II,
Item 1A. "Risk Factors" in Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K, or other filings with the SEC.
For additional information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartware.com
Phone: +1 508 739 0864
Logo - http://photos.prnewswire.com/prnh/20150901/262901LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/heartware-announces-hvad-system-scientific-presentations-at-the-international-society-for-heart-and-lung-transplantation-36th-annual-meeting-300254352.html
SOURCE HeartWare International, Inc.